BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Drug Development

  BerGenBio Announces Start Of Phase II Trial Assessing Selective AXL Inhibitor BGB324 In Combination With KEYTRUDA For Patients With Advanced Breast Cancer

  BerGenBio announces that the first patient has been dosed in a Phase II trial evaluating the Company’s lead product BGB324 in combination with KEYTRUDA (pembrolizumab).

  October 19, 2017

   · 

  4 min read
• Business

  Median Technologies Appoints Vivian Wang As General Manager, China and Takashi Hayashi As Managing Director, Japan

  Median Technologies, The Imaging Phenomics Company today announces the appointment of Vivian Wang as General Manager, China and the appointment of Takashi Hayashi as Managing Director, Japan.

  October 19, 2017

   · 

  5 min read
• Business

  AMAG Pharmaceuticals to Host Third Quarter 2017 Financial Results Conference Call and Webcast on Thursday, November 2, 2017 at 8:00 a.m. ET

  Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.

  October 19, 2017

   · 

  1 min read
• Drug Development

  Atara Biotherapeutics Initiates 60 Patient, Global Phase 1 Clinical Study to Evaluate Allogeneic ATA188 in Patients with Progressive or Relapsing-Remitting Multiple Sclerosis (MS)

  Enrollment to begin in Australia; U.S. sites expected to open in early 2018.

  October 19, 2017

   · 

  7 min read
• Drug Development

  Calithera Announces First Patient Treated in Phase I Cohort of INCB01158 Dosed in Combination With Keytruda

  The Phase 1 trial is designed to evaluate the safety and recommended Phase 2 dose of INCB01158 as a monotherapy, and in combination with immune checkpoint therapy.

  October 19, 2017

   · 

  4 min read
• Bio-Rad Release: Genomics Researchers Showcase Their Applications Of Droplet Digital PCR At ASHG 2017 Annual Meeting

  The sensitivity and reliability of Droplet Digital PCR will be showcased in over a dozen presentations at the American Society of Human Genetics (ASHG) 2017 Annual Meeting, Orlando, Fla., October 17-21.

  October 19, 2017

   · 

  4 min read
• Business

  Harvard Bioscience Schedules Third Quarter 2017 Conference Call for October 26 at 4:30 PM ET

  A conference call to discuss the company’s third quarter 2017 financial results and its operations is scheduled for that same date at 4:30 PM ET.

  October 19, 2017

   · 

  1 min read
• Drug Development

  Creative Medical Technology Announces Commercialization of Patented Stem Cell Procedure for Erectile Dysfunction

  Creative Medical Technology Holdings announced today completion of the safety data analysis on 20 patients with pharmacologically-resistant erectile dysfunction treated with the Company’s patented CaverStem procedure.

  October 19, 2017

   · 

  3 min read
• Drug Development

  ContraVir Pharmaceuticals Initiated Dosing of Renally-Impaired Patients in First U.S. Trial With TXL

  October 19, 2017

   · 

  3 min read
• Drug Development

  OSE Immunotherapeutics Publishes New Data on FR104, CD28-Antagonist Immunotherapy

  FR104 shows immune tolerance superiority over CTLA4-Ig in humanized skin transplant model.

  October 19, 2017

   · 

  8 min read